AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension
← catalyst calendarNCT04499248 · readout ≤ 985 d
Sponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
Phase 1/2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
100actual
Sites
49
Countries
Japan, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2020-11-16 | actual | When the study began enrolling |
| Primary completion | Apr 2029 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Apr 2029 | estimated | The whole study's end, after follow-up |
| First posted | 2020-08-05 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Open-angle Glaucoma
- Ocular Hypertension
Interventions
- Drug: AGN-193408 SR
- Other: Lumigan — also filed as Active Comparator
- Other: Sham Administration
- Other: Lumigan Vehicle — also filed as Vehicle
- Drug: AGN-193408 SR
- Other: Sham Administration
- Other: Lumigan Vehicle — also filed as Vehicle
Primary outcomes
what the primary-completion date above is the date OFChange from Baseline in Hour 0 Intraocular Pressure (IOP) in the Study Eye
measured Baseline to Month 36
Number of participants experiencing treatment emergent adverse events
measured Baseline to Month 36
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed